As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Haemonetics Corp. The largest reported stake is Vanguard Portfolio Management's, at 5.59%. 8 filings are on record since August 12, 2025 (Schedule 13G, April 29, 2026).
Sell to companies like Haemonetics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: AQR Capital Management, LLC · Sole voting: 0 · Shared voting: 2,149,735 · Sole dispositive: 0 · Shared dispositive: 2,266,489 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: North Peak Capital Management, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-13
- · Reporting person: Vanguard Capital Management · Sole voting: 355,428 · Shared voting: 0 · Sole dispositive: 2,445,817 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-30
- · Reporting person: Vanguard Portfolio Management · Sole voting: 40,829 · Shared voting: 0 · Sole dispositive: 2,600,145 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Haemonetics Corp has 8 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Vanguard Portfolio Management | 5.59% | 2,600,145 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Vanguard Capital Management | 5.26% | 2,445,817 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| AQR Capital Management, LLC | 4.99% | 2,266,489 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Wellington Management Group LLP | 4.6% | 2,203,351 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| North Peak Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Haemonetics Corp and the warning signs.
Free to see. No signup.
Keep reading
More on Haemonetics Corp and the records around it.
Haemonetics Corp elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- North Peak Capital Management, LLC also filed stake reports on 2 other companies: GMR Solutions Inc. (Aug 2026), agilon health, inc. (Nov 2025)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Watch Haemonetics Corp
Get an email when Haemonetics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Haemonetics Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Haemonetics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Haemonetics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Vanguard Portfolio Management | 40,829 | 0 | 2,600,145 | 0 | SCHEDULE 13G, 2026-04-29 |
| Vanguard Capital Management | 355,428 | 0 | 2,445,817 | 0 | SCHEDULE 13G, 2026-04-30 |
| AQR Capital Management, LLC | 0 | 2,149,735 | 0 | 2,266,489 | SCHEDULE 13G/A, 2026-08-12 |
| AQR Capital Management Holdings, LLC | 0 | 2,149,735 | 0 | 2,266,489 | SCHEDULE 13G/A, 2026-08-12 |
| North Peak Capital Management, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| North Peak Capital GP, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| North Peak Capital Partners, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| North Peak Capital Partners II, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| North Peak Capital Alpha Fund, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| North Peak Capital Ultra Fund, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| Michael Kevin Kahan | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
| Jeremy Steven Kahan | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-13 |
The latest filing identifies Haemonetics Corp by CUSIP 405024100 and gives its principal executive office as 125 SUMMER STREET, BOSTON, MA 02110 (SCHEDULE 13G/A, 2026-08-12).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Wellington Management Group LLP | 4.6% | SCHEDULE 13G/A |
| 2026-02-13 | AQR Capital Management, LLC | 6.76% | SCHEDULE 13G |
| 2026-03-03 | North Peak Capital Management, LLC | 5.1% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.59% | SCHEDULE 13G |
| 2026-04-30 | Vanguard Capital Management | 5.26% | SCHEDULE 13G |
| 2026-05-13 | North Peak Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-08-12 | AQR Capital Management, LLC | 4.99% | SCHEDULE 13G/A |
Questions about who owns Haemonetics Corp
Who owns Haemonetics Corp?
On this page, 2 holders' latest ownership filings report 5% or more of Haemonetics Corp: Vanguard Portfolio Management (5.59%, Schedule 13G, filed 2026-04-29) and Vanguard Capital Management (5.26%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Haemonetics Corp?
By the share each holder's latest filing reports, the largest holders of Haemonetics Corp on this page are Vanguard Portfolio Management (5.59%) and Vanguard Capital Management (5.26%).
When did Vanguard Portfolio Management buy into Haemonetics Corp?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Portfolio Management on this page is the Schedule 13G, filed 2026-04-29, reporting 5.59%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Haemonetics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 28, 2026 | Leadership change: Martin Madaus appointed, Director | — | Leadership changes | Source |
| May 1, 2026 | Leadership change: Charles J. Dockendorff departs | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Haemonetics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.